Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with  Velcade (bortezomib) with dexamethasone — information that …
News
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of…
Kadmon reports that the first patient group treated in a Phase 2 trial of its drug KD025 for chronic graft-versus-host disease after going through…
The Multiple Myeloma Research Foundation will be pumping $15 million into a cancer immunotherapy initiative over the next three years. The effort will start with the…
The U.S. Food and Drug Administration (FDA) has ordered Merck to suspend two Phase 3 and part of a…
The U.S. Food and Drug Administration (FDA) recently approved a lab test to aid in the detection and diagnosis of myeloma and a range of…
Treatment with Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ELd) in patients with relapsed/refractory multiple myeloma (RRMM) continued to show effectiveness in the Phase 3…
Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed by Ninlaro maintenance therapy, according…
Doctors told Don Wright he had five years to live when he was diagnosed with multiple myeloma in 2003. Instead of resigning himself to this…
The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) seeking to expand the currently approved indication of Xgeva…
